DE2423529A1 - Mittel zur behandlung neurologischer stoerungen - Google Patents

Mittel zur behandlung neurologischer stoerungen

Info

Publication number
DE2423529A1
DE2423529A1 DE2423529A DE2423529A DE2423529A1 DE 2423529 A1 DE2423529 A1 DE 2423529A1 DE 2423529 A DE2423529 A DE 2423529A DE 2423529 A DE2423529 A DE 2423529A DE 2423529 A1 DE2423529 A1 DE 2423529A1
Authority
DE
Germany
Prior art keywords
caffeine
dopa
theophyllamine
papaverine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE2423529A
Other languages
German (de)
English (en)
Inventor
Spaeter Genannt Werden Wird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra Lakemedel AB
Original Assignee
Astra Lakemedel AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE7306960A external-priority patent/SE7306960L/xx
Application filed by Astra Lakemedel AB filed Critical Astra Lakemedel AB
Publication of DE2423529A1 publication Critical patent/DE2423529A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE2423529A 1973-05-17 1974-05-15 Mittel zur behandlung neurologischer stoerungen Pending DE2423529A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7306960A SE7306960L (enExample) 1973-05-17

Publications (1)

Publication Number Publication Date
DE2423529A1 true DE2423529A1 (de) 1974-12-05

Family

ID=20317502

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2423529A Pending DE2423529A1 (de) 1973-05-17 1974-05-15 Mittel zur behandlung neurologischer stoerungen

Country Status (7)

Country Link
US (1) US3961060A (enExample)
JP (1) JPS5029716A (enExample)
AU (1) AU6889274A (enExample)
DE (1) DE2423529A1 (enExample)
FI (1) FI152074A7 (enExample)
FR (1) FR2229412A1 (enExample)
NL (1) NL7406689A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5753712A (en) * 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
WO2001032170A1 (en) * 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
CA2410531A1 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Combination therapy for treatment of depression
IT1317049B1 (it) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
US20030092770A1 (en) * 2002-10-23 2003-05-15 Phil Skolnick Combination therapy for treatment of depression
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
WO2004074247A2 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US9364474B2 (en) 2004-09-20 2016-06-14 Meddev Inc. Method for treatment of neurologic dysfunction
US7645766B1 (en) * 2004-09-20 2010-01-12 MedDEV, Inc. Method for treatment of depression and depressive mood disorders
US8440685B1 (en) 2004-09-20 2013-05-14 MedDEV, Inc. Method for treatment of neurologic dysfunction
ES2627655T3 (es) * 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
WO2013016662A1 (en) * 2011-07-28 2013-01-31 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
HK1219416A1 (zh) 2013-03-08 2017-04-07 Benjamin M. YU 以溶液或悬浮液的形式透皮传输咖啡因的方法和成分
AU2015229521A1 (en) 2014-03-10 2016-09-01 Benjamin M. YU Methods and compositions for transdermal delivery
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PT3116475T (pt) 2014-03-13 2020-12-15 Neuroderm Ltd Composições de inibidores de dopa-descarboxilase
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646213A (en) * 1970-08-12 1972-02-29 Hoffmann La Roche Compositions and methods for treating depression with combinations of l-3 4-dihydroxyphenylalanine and a hydrazine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome

Also Published As

Publication number Publication date
AU6889274A (en) 1975-11-20
JPS5029716A (enExample) 1975-03-25
FR2229412A1 (enExample) 1974-12-13
US3961060A (en) 1976-06-01
NL7406689A (enExample) 1974-11-19
FI152074A7 (enExample) 1974-11-18

Similar Documents

Publication Publication Date Title
DE2423529A1 (de) Mittel zur behandlung neurologischer stoerungen
DE60019473T2 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE19542281C2 (de) Verwendung von Epinastin für die Behandlung der Migräne
DE69400799T2 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60218193T2 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE2856393A1 (de) Mittel zur behandlung des zentralnervensystems
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE3415394A1 (de) Medikament gegen ovarialinsuffizienz
DE4135551A1 (de) Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
DE3130912A1 (de) Analgetische arzneimittelkombination
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
DE3445183A1 (de) Proglumide enthaltende arzneimittel mit analgetischer wirkung
DE3525390C2 (enExample)
EP0161501A1 (de) Antiulcermittel zur Behandlung von Geschwüren
DE60122252T2 (de) Verfahren zur behandlung von neurodegeneration
DE2823268C2 (enExample)
DE3736866A1 (de) Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
EP0013252B1 (de) Mittel zur Senkung der Herzfrequenz
EP0417637A2 (de) Verwendung von Dopamin-Autorezeptor-Agonisten bei der Behandlung von Drogenabhängigkeit
DE3030345A1 (de) Verfahren zur behebung oder linderung von herpes-infektionen und hierzu geeignete pharmazeutische zusammensetzungen
DE2823267C2 (enExample)
DE2755017C2 (enExample)
DE10318714B4 (de) Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
EP1307195A2 (de) Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten